<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00359788</url>
  </required_header>
  <id_info>
    <org_study_id>205.325</org_study_id>
    <nct_id>NCT00359788</nct_id>
  </id_info>
  <brief_title>A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent Inhalation Aerosol in COPD Patients.</brief_title>
  <official_title>A Randomized, Double-blind, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium 18 mcg Daily to Combivent MDI 2 Actuations Qid in COPD Patients Previously Prescribed Combivent MDI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy and safety of 12 weeks treatment with
      tiotropium HandiHaler 18 micrograms (mcg) daily compared to Combivent Metered Dose Inhaler
      (MDI) Chlorofluorocarbon Inhalation Aerosol 2 actuations four times a day in Chronic
      Obstructive Pulmonary Disease (COPD) patients currently prescribed CombiventÂ® MDI.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Trough FEV1 (Forced Expiratory Volume in 1 Second) at 12 Weeks</measure>
    <time_frame>Baseline and 12 Weeks</time_frame>
    <description>Trough FEV1 is measured 10 minutes before drug administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Average Hourly FEV1 AUC0-6 (Area Under the Curve From Zero to Six Hours) at 12 Weeks</measure>
    <time_frame>Baseline and 12 Weeks</time_frame>
    <description>Average hourly FEV1 AUC0-6 minus baseline FEV1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough FEV1 (Forced Expiratory Volume in 1 Second) at 6 Weeks</measure>
    <time_frame>Baseline and 6 Weeks</time_frame>
    <description>Trough FEV1 is measured 10 minutes before drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Hourly FEV1 AUC0-6 (Area Under the Curve From Zero to Six Hours) on Day 1</measure>
    <time_frame>Day 1 (after first dose)</time_frame>
    <description>Average hourly FEV1 AUC0-6 minus baseline FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Hourly FEV1 AUC0-6 (Area Under the Curve From Zero to Six Hours) at Week 6</measure>
    <time_frame>Baseline and week 6</time_frame>
    <description>Average hourly FEV1 AUC0-6 minus baseline FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Peak FEV1 (Forced Expiratory Volume in 1 Second) on Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Peak FEV1 is defined as the maximum FEV1 observed in the first three hours after dose of study medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Peak FEV1 (Forced Expiratory Volume in 1 Second) at Week 6</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Peak FEV1 is defined as the maximum FEV1 observed in the first three hours after dose of study medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Peak FEV1 (Forced Expiratory Volume in 1 Second) at Week 12</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Peak FEV1 is defined as the maximum FEV1 observed in the first three hours after dose of study medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough FVC (Forced Vital Capacity) at 12 Weeks</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Trough FVC is measured 10 minutes before drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Hourly FVC AUC0-6 (Area Under the Curve From Zero to Six Hours) at 12 Weeks</measure>
    <time_frame>Baseline and 12 Weeks</time_frame>
    <description>Average hourly FVC AUC0-6 minus baseline FVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough FVC (Forced Vital Capacity) at 6 Weeks</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Trough FVC is measured 10 minutes before drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Hourly FVC AUC0-6 (Area Under the Curve From Zero to Six Hours) on Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Average hourly FVC AUC0-6 minus baseline FVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Hourly FVC AUC0-6 (Area Under the Curve From Zero to Six Hours) at 6 Weeks</measure>
    <time_frame>Baseline and 6 Weeks</time_frame>
    <description>Average hourly FVC AUC0-6 minus baseline FVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Peak FVC (Forced Vital Capacity) on Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Peak FVC is defined as the maximum FVC observed in the first three hours after dose of study medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Peak FVC (Forced Vital Capacity) at Week 6</measure>
    <time_frame>baseline and 6 Weeks (after first dose)</time_frame>
    <description>Peak FVC is defined as the maximum FVC observed in the first three hours after dose of study medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Peak FVC (Forced Vital Capacity) at Week 12</measure>
    <time_frame>Baseline and 12 Weeks</time_frame>
    <description>Peak FVC is defined as the maximum FVC observed in the first three hours after dose of study medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 at 15 Minutes on Day 1</measure>
    <time_frame>15 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 at 30 Minutes on Day 1</measure>
    <time_frame>30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 at 1 Hour on Day 1</measure>
    <time_frame>1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 at 2 Hours on Day 1</measure>
    <time_frame>2 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 at 3 Hours on Day 1</measure>
    <time_frame>3 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 at 4 Hours on Day 1</measure>
    <time_frame>4 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 at 6 Hours on Day 1</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 at -10 Minutes at Week 6</measure>
    <time_frame>10 minutes before dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 at 15 Minutes at Week 6</measure>
    <time_frame>15 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 at 30 Minutes at Week 6</measure>
    <time_frame>30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 at 1 Hour at Week 6</measure>
    <time_frame>1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 at 2 Hours at Week 6</measure>
    <time_frame>2 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 at 3 Hours at Week 6</measure>
    <time_frame>3 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 at 4 Hours at Week 6</measure>
    <time_frame>4 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 at 6 Hours at Week 6</measure>
    <time_frame>6 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 at -10 Minutes at Week 12</measure>
    <time_frame>10 minutes before dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 at 15 Minutes at Week 12</measure>
    <time_frame>15 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 at 30 Minutes at Week 12</measure>
    <time_frame>30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 at 1 Hour at Week 12</measure>
    <time_frame>1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 at 2 Hours at Week 12</measure>
    <time_frame>2 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 at 3 Hours at Week 12</measure>
    <time_frame>3 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 at 4 Hours at Week 12</measure>
    <time_frame>4 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 at 6 Hours at Week 12</measure>
    <time_frame>6 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC at 15 Minutes on Day 1</measure>
    <time_frame>15 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC at 30 Minutes on Day 1</measure>
    <time_frame>30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC at 1 Hour on Day 1</measure>
    <time_frame>1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC at 2 Hours on Day 1</measure>
    <time_frame>2 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC at 3 Hours on Day 1</measure>
    <time_frame>3 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC at 4 Hours on Day 1</measure>
    <time_frame>4 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC at 6 Hours on Day 1</measure>
    <time_frame>6 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC at -10 Minutes at Week 6</measure>
    <time_frame>10 minutes before dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC at 15 Minutes at Week 6</measure>
    <time_frame>15 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC at 30 Minutes at Week 6</measure>
    <time_frame>30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC at 1 Hour at Week 6</measure>
    <time_frame>1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC at 2 Hours at Week 6</measure>
    <time_frame>2 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC at 3 Hours at Week 6</measure>
    <time_frame>3 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC at 4 Hours at Week 6</measure>
    <time_frame>4 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC at 6 Hours at Week 6</measure>
    <time_frame>6 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC at -10 Minutes at Week 12</measure>
    <time_frame>10 minutes before dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC at 15 Minutes at Week 12</measure>
    <time_frame>15 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC at 30 Minutes at Week 12</measure>
    <time_frame>30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC at 1 Hour at Week 12</measure>
    <time_frame>1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC at 2 Hours at Week 12</measure>
    <time_frame>2 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC at 3 Hours at Week 12</measure>
    <time_frame>3 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC at 4 Hours at Week 12</measure>
    <time_frame>4 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC at 6 Hours at Week 12</measure>
    <time_frame>6 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day Time Albuterol Use During Week 1</measure>
    <time_frame>Week 1</time_frame>
    <description>Puffs of rescue albuterol used during the day in week 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day Time Albuterol Use During Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Puffs of rescue albuterol used during the day in week 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day Time Albuterol Use During Week 3</measure>
    <time_frame>Week 3</time_frame>
    <description>Puffs of rescue albuterol used during the day in week 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day Time Albuterol Use During Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Puffs of rescue albuterol used during the day in week 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day Time Albuterol Use During Week 5</measure>
    <time_frame>Week 5</time_frame>
    <description>Puffs of rescue albuterol used during the day in week 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day Time Albuterol Use During Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Puffs of rescue albuterol used during the day in week 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day Time Albuterol Use During Week 7</measure>
    <time_frame>Week 7</time_frame>
    <description>Puffs of rescue albuterol used during the day in week 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day Time Albuterol Use During Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Puffs of rescue albuterol used during the day in week 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day Time Albuterol Use During Week 9</measure>
    <time_frame>Week 9</time_frame>
    <description>Puffs of rescue albuterol used during the day in week 9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day Time Albuterol Use During Week 10</measure>
    <time_frame>Week 10</time_frame>
    <description>Puffs of rescue albuterol used during the day in week 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day Time Albuterol Use During Week 11</measure>
    <time_frame>Week 11</time_frame>
    <description>Puffs of rescue albuterol used during the day in week 11</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day Time Albuterol Use During Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Puffs of rescue albuterol used during the day in week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Night Time Albuterol Use During Week 1</measure>
    <time_frame>Week 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Night Time Albuterol Use During Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Puffs of rescue albuterol used during the night in week 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Night Time Albuterol Use During Week 3</measure>
    <time_frame>Week 3</time_frame>
    <description>Puffs of rescue albuterol used during the night in week 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Night Time Albuterol Use During Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Puffs of rescue albuterol used during the night in week 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Night Time Albuterol Use During Week 5</measure>
    <time_frame>Week 5</time_frame>
    <description>Puffs of rescue albuterol used during the night in week 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Night Time Albuterol Use During Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Puffs of rescue albuterol used during the night in week 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Night Time Albuterol Use During Week 7</measure>
    <time_frame>Week 7</time_frame>
    <description>Puffs of rescue albuterol used during the night in week 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Night Time Albuterol Use During Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Puffs of rescue albuterol used during the night in week 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Night Time Albuterol Use During Week 9</measure>
    <time_frame>Week 9</time_frame>
    <description>Puffs of rescue albuterol used during the night in week 9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Night Time Albuterol Use During Week 10</measure>
    <time_frame>Week 10</time_frame>
    <description>Puffs of rescue albuterol used during the night in week 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Night Time Albuterol Use During Week 11</measure>
    <time_frame>Week 11</time_frame>
    <description>Puffs of rescue albuterol used during the night in week 11</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Night Time Albuterol Use During Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Puffs of rescue albuterol used during the night in week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning Peak Expiratory Flow Rate (PEFR) at Week 1</measure>
    <time_frame>Week 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning PEFR at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Weekly means for morning PEFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning PEFR at Week 3</measure>
    <time_frame>Week 3</time_frame>
    <description>Weekly means for morning PEFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning PEFR at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Weekly means for morning PEFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning PEFR at Week 5</measure>
    <time_frame>Week 5</time_frame>
    <description>Weekly means for morning PEFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning PEFR at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Weekly means for morning PEFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning PEFR at Week 7</measure>
    <time_frame>Week 7</time_frame>
    <description>Weekly means for morning PEFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning PEFR at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Weekly means for morning PEFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning PEFR at Week 9</measure>
    <time_frame>Week 9</time_frame>
    <description>Weekly means for morning PEFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning PEFR at Week 10</measure>
    <time_frame>Week 10</time_frame>
    <description>Weekly means for morning PEFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning PEFR at Week 11</measure>
    <time_frame>Week 11</time_frame>
    <description>Weekly means for morning PEFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning PEFR at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Weekly means for morning PEFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evening PEFR at Week 1</measure>
    <time_frame>Week 1</time_frame>
    <description>Weekly means for evening PEFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evening PEFR at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Weekly means for evening PEFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evening PEFR at Week 3</measure>
    <time_frame>Week 3</time_frame>
    <description>Weekly means for evening PEFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evening PEFR at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Weekly means for evening PEFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evening PEFR at Week 5</measure>
    <time_frame>Week 5</time_frame>
    <description>Weekly means for evening PEFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evening PEFR at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Weekly means for evening PEFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evening PEFR at Week 7</measure>
    <time_frame>Week 7</time_frame>
    <description>Weekly means for evening PEFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evening PEFR at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Weekly means for evening PEFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evening PEFR at Week 9</measure>
    <time_frame>Week 9</time_frame>
    <description>Weekly means for evening PEFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evening PEFR at Week 10</measure>
    <time_frame>Week 10</time_frame>
    <description>Weekly means for evening PEFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evening PEFR at Week 11</measure>
    <time_frame>Week 11</time_frame>
    <description>Weekly means for evening PEFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evening PEFR at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Weekly means for evening PEFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Evaluation</measure>
    <time_frame>Week 6</time_frame>
    <description>The Patient Global Evaluation reflected the patient's opinion of their overall condition with respect to chronic obstructive pulmonary disease (COPD). The scale responses were: Poor (1,2). Fair (3,4), Good (5,6) and Excellent (7,8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Evaluation</measure>
    <time_frame>Week 12</time_frame>
    <description>The Patient Global Evaluation reflected the patient's opinion of their overall condition with respect to COPD. The scale responses were: Poor (1,2). Fair (3,4), Good (5,6) and Excellent (7,8).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Global Evaluation</measure>
    <time_frame>Week 6</time_frame>
    <description>The Physician Global Evaluation reflected the physician's opinion of the patients overall condition with respect to COPD. The scale responses were: Poor (1,2). Fair (3,4), Good (5,6) and Excellent (7,8).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Global Evaluation</measure>
    <time_frame>Week 12</time_frame>
    <description>The Physician Global Evaluation reflected the physician's opinion of the patients overall condition with respect to COPD. The scale responses were: Poor (1,2). Fair (3,4), Good (5,6) and Excellent (7,8).</description>
  </secondary_outcome>
  <enrollment type="Actual">349</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combivent (Ipratropium/Albuterol)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) Age: greater
        than or equal to 40 years

          -  Current or ex-smoker with a &gt;= 10 pack-year smoking history

          -  Use of CombiventÂ® Metered Dose Inhaler (MDI)for &gt;= 1 month prior to Visit 1

        Spirometric criteria (determined at study visits):

          -  Post-bronchodilator Forced Expiratory Volume in one second (FEV1) &lt;= 70% (Visit 1)

          -  Pre-bronchodilator FEV1 &lt;= 65% of predicted and FEV1/Forced Vital Capacity (FVC) &lt;=
             70% (Visit 2)

        Exclusion Criteria:

        Clinical history of asthma

          -  History of thoracotomy with pulmonary resection

          -  History of Cystic Fibrosis, alpha 1 antitrypsin deficiency or interstitial lung
             disease

          -  Daytime use of oxygen therapy for &gt; 1 hour per day or if unable to abstain fr om using
             oxygen during Pulmonary Function Tests

          -  Any respiratory tract infection or COPD exacerbation in 6 weeks prior to Visit 1

          -  Recent history 6 months or less of Myocardial Infarction

          -  Unstable or life-threatening cardiac arrhythmias

          -  Hospitalization for Congestive Heart Failure during past year

          -  Malignancy for which patient is receiving chemo or radiation therapy

          -  Pregnant or nursing women

          -  Known hypersensitivity to ipratropium or carrier substances, including related food
             products such as soybean, peanuts, or lactose

          -  Use of SPIRIVAÂ® 3 months prior to Visit 1

          -  Symptomatic of prostatic hypertrophy or bladder neck obstruction

          -  Known narrow- angle glaucoma

          -  Participating in a pulmonary rehab program within 4 weeks of Visit 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>205.325.904 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.325.925 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.325.909 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.325.912 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.325.911 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.325.935 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.325.903 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.325.905 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bay Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.325.922 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.325.907 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>North Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.325.928 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Indiananapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.325.923 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.325.902 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.325.908 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.325.920 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.325.932 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.325.915 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.325.914 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.325.910 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.325.924 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>East Orange</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.325.921 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.325.917 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.325.926 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.325.901 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.325.931 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.325.929 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.325.936 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.325.918 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.325.927 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.325.919 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.325.906 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2006</study_first_submitted>
  <study_first_submitted_qc>August 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2006</study_first_posted>
  <results_first_submitted>April 17, 2009</results_first_submitted>
  <results_first_submitted_qc>October 5, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 10, 2009</results_first_posted>
  <last_update_submitted>May 7, 2014</last_update_submitted>
  <last_update_submitted_qc>May 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Ipratropium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tiotropium</title>
          <description>18 mcg once daily</description>
        </group>
        <group group_id="P2">
          <title>Combivent (Ipratropium/Albuterol)</title>
          <description>2 actuations 4 times daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="173"/>
                <participants group_id="P2" count="176"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="150"/>
                <participants group_id="P2" count="159"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tiotropium</title>
          <description>18 mcg once daily</description>
        </group>
        <group group_id="B2">
          <title>Combivent (Ipratropium/Albuterol)</title>
          <description>2 actuations 4 times daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="173"/>
            <count group_id="B2" value="176"/>
            <count group_id="B3" value="349"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.7" spread="7.7"/>
                    <measurement group_id="B2" value="65.4" spread="8"/>
                    <measurement group_id="B3" value="65.1" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="33.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                    <measurement group_id="B2" value="163"/>
                    <measurement group_id="B3" value="316.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Trough FEV1 (Forced Expiratory Volume in 1 Second) at 12 Weeks</title>
        <description>Trough FEV1 is measured 10 minutes before drug administration</description>
        <time_frame>Baseline and 12 Weeks</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough FEV1 (Forced Expiratory Volume in 1 Second) at 12 Weeks</title>
          <description>Trough FEV1 is measured 10 minutes before drug administration</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.081" spread="0.018"/>
                    <measurement group_id="O2" value="-0.025" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.106</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.055</ci_lower_limit>
            <ci_upper_limit>0.157</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Average Hourly FEV1 AUC0-6 (Area Under the Curve From Zero to Six Hours) at 12 Weeks</title>
        <description>Average hourly FEV1 AUC0-6 minus baseline FEV1</description>
        <time_frame>Baseline and 12 Weeks</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Hourly FEV1 AUC0-6 (Area Under the Curve From Zero to Six Hours) at 12 Weeks</title>
          <description>Average hourly FEV1 AUC0-6 minus baseline FEV1</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.187" spread="0.019"/>
                    <measurement group_id="O2" value="0.167" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin = 0.05 liters</non_inferiority_desc>
            <p_value>0.0042</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.032</ci_lower_limit>
            <ci_upper_limit>0.072</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough FEV1 (Forced Expiratory Volume in 1 Second) at 6 Weeks</title>
        <description>Trough FEV1 is measured 10 minutes before drug administration</description>
        <time_frame>Baseline and 6 Weeks</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough FEV1 (Forced Expiratory Volume in 1 Second) at 6 Weeks</title>
          <description>Trough FEV1 is measured 10 minutes before drug administration</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.017"/>
                    <measurement group_id="O2" value="-0.036" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.145</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.098</ci_lower_limit>
            <ci_upper_limit>0.193</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Average Hourly FEV1 AUC0-6 (Area Under the Curve From Zero to Six Hours) on Day 1</title>
        <description>Average hourly FEV1 AUC0-6 minus baseline FEV1</description>
        <time_frame>Day 1 (after first dose)</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Hourly FEV1 AUC0-6 (Area Under the Curve From Zero to Six Hours) on Day 1</title>
          <description>Average hourly FEV1 AUC0-6 minus baseline FEV1</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.132" spread="0.012"/>
                    <measurement group_id="O2" value="0.211" spread="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.114</ci_lower_limit>
            <ci_upper_limit>-0.046</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Average Hourly FEV1 AUC0-6 (Area Under the Curve From Zero to Six Hours) at Week 6</title>
        <description>Average hourly FEV1 AUC0-6 minus baseline FEV1</description>
        <time_frame>Baseline and week 6</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Hourly FEV1 AUC0-6 (Area Under the Curve From Zero to Six Hours) at Week 6</title>
          <description>Average hourly FEV1 AUC0-6 minus baseline FEV1</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.207" spread="0.019"/>
                    <measurement group_id="O2" value="0.153" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0447</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.054</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.001</ci_lower_limit>
            <ci_upper_limit>0.106</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Peak FEV1 (Forced Expiratory Volume in 1 Second) on Day 1</title>
        <description>Peak FEV1 is defined as the maximum FEV1 observed in the first three hours after dose of study medication</description>
        <time_frame>Day 1</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Peak FEV1 (Forced Expiratory Volume in 1 Second) on Day 1</title>
          <description>Peak FEV1 is defined as the maximum FEV1 observed in the first three hours after dose of study medication</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.232" spread="0.014"/>
                    <measurement group_id="O2" value="0.364" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.131</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.171</ci_lower_limit>
            <ci_upper_limit>-0.092</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Peak FEV1 (Forced Expiratory Volume in 1 Second) at Week 6</title>
        <description>Peak FEV1 is defined as the maximum FEV1 observed in the first three hours after dose of study medication</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Peak FEV1 (Forced Expiratory Volume in 1 Second) at Week 6</title>
          <description>Peak FEV1 is defined as the maximum FEV1 observed in the first three hours after dose of study medication</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.204" spread="0.014"/>
                    <measurement group_id="O2" value="0.356" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.152</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>-0.113</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Peak FEV1 (Forced Expiratory Volume in 1 Second) at Week 12</title>
        <description>Peak FEV1 is defined as the maximum FEV1 observed in the first three hours after dose of study medication</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Peak FEV1 (Forced Expiratory Volume in 1 Second) at Week 12</title>
          <description>Peak FEV1 is defined as the maximum FEV1 observed in the first three hours after dose of study medication</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.209" spread="0.015"/>
                    <measurement group_id="O2" value="0.342" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.133</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.175</ci_lower_limit>
            <ci_upper_limit>-0.091</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough FVC (Forced Vital Capacity) at 12 Weeks</title>
        <description>Trough FVC is measured 10 minutes before drug administration</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough FVC (Forced Vital Capacity) at 12 Weeks</title>
          <description>Trough FVC is measured 10 minutes before drug administration</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.225" spread="0.039"/>
                    <measurement group_id="O2" value="0.051" spread="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0015</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.175</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.067</ci_lower_limit>
            <ci_upper_limit>0.283</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Average Hourly FVC AUC0-6 (Area Under the Curve From Zero to Six Hours) at 12 Weeks</title>
        <description>Average hourly FVC AUC0-6 minus baseline FVC</description>
        <time_frame>Baseline and 12 Weeks</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Hourly FVC AUC0-6 (Area Under the Curve From Zero to Six Hours) at 12 Weeks</title>
          <description>Average hourly FVC AUC0-6 minus baseline FVC</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.443" spread="0.037"/>
                    <measurement group_id="O2" value="0.432" spread="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.835</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.011</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.092</ci_lower_limit>
            <ci_upper_limit>0.114</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough FVC (Forced Vital Capacity) at 6 Weeks</title>
        <description>Trough FVC is measured 10 minutes before drug administration</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough FVC (Forced Vital Capacity) at 6 Weeks</title>
          <description>Trough FVC is measured 10 minutes before drug administration</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.258" spread="0.036"/>
                    <measurement group_id="O2" value="-0.02" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.278</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.178</ci_lower_limit>
            <ci_upper_limit>0.379</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Average Hourly FVC AUC0-6 (Area Under the Curve From Zero to Six Hours) on Day 1</title>
        <description>Average hourly FVC AUC0-6 minus baseline FVC</description>
        <time_frame>Day 1</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Hourly FVC AUC0-6 (Area Under the Curve From Zero to Six Hours) on Day 1</title>
          <description>Average hourly FVC AUC0-6 minus baseline FVC</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.327" spread="0.028"/>
                    <measurement group_id="O2" value="0.484" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.157</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.236</ci_lower_limit>
            <ci_upper_limit>-0.078</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Average Hourly FVC AUC0-6 (Area Under the Curve From Zero to Six Hours) at 6 Weeks</title>
        <description>Average hourly FVC AUC0-6 minus baseline FVC</description>
        <time_frame>Baseline and 6 Weeks</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Hourly FVC AUC0-6 (Area Under the Curve From Zero to Six Hours) at 6 Weeks</title>
          <description>Average hourly FVC AUC0-6 minus baseline FVC</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.464" spread="0.035"/>
                    <measurement group_id="O2" value="0.425" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4386</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.039</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.059</ci_lower_limit>
            <ci_upper_limit>0.137</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Peak FVC (Forced Vital Capacity) on Day 1</title>
        <description>Peak FVC is defined as the maximum FVC observed in the first three hours after dose of study medication</description>
        <time_frame>Day 1</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Peak FVC (Forced Vital Capacity) on Day 1</title>
          <description>Peak FVC is defined as the maximum FVC observed in the first three hours after dose of study medication</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.542" spread="0.033"/>
                    <measurement group_id="O2" value="0.824" spread="0.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.282</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.374</ci_lower_limit>
            <ci_upper_limit>-0.191</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Peak FVC (Forced Vital Capacity) at Week 6</title>
        <description>Peak FVC is defined as the maximum FVC observed in the first three hours after dose of study medication</description>
        <time_frame>baseline and 6 Weeks (after first dose)</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Peak FVC (Forced Vital Capacity) at Week 6</title>
          <description>Peak FVC is defined as the maximum FVC observed in the first three hours after dose of study medication</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.031"/>
                    <measurement group_id="O2" value="0.791" spread="0.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.361</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.449</ci_lower_limit>
            <ci_upper_limit>-0.274</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Peak FVC (Forced Vital Capacity) at Week 12</title>
        <description>Peak FVC is defined as the maximum FVC observed in the first three hours after dose of study medication</description>
        <time_frame>Baseline and 12 Weeks</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Peak FVC (Forced Vital Capacity) at Week 12</title>
          <description>Peak FVC is defined as the maximum FVC observed in the first three hours after dose of study medication</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.418" spread="0.032"/>
                    <measurement group_id="O2" value="0.703" spread="0.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.286</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.375</ci_lower_limit>
            <ci_upper_limit>-0.196</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 at 15 Minutes on Day 1</title>
        <time_frame>15 minutes</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 at 15 Minutes on Day 1</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.214" spread="0.012"/>
                    <measurement group_id="O2" value="1.389" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.175</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.207</ci_lower_limit>
            <ci_upper_limit>-0.142</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 at 30 Minutes on Day 1</title>
        <time_frame>30 minutes</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 at 30 Minutes on Day 1</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.261" spread="0.013"/>
                    <measurement group_id="O2" value="1.429" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.168</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.205</ci_lower_limit>
            <ci_upper_limit>-0.131</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 at 1 Hour on Day 1</title>
        <time_frame>1 hour</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 at 1 Hour on Day 1</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.272" spread="0.014"/>
                    <measurement group_id="O2" value="1.455" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.182</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.221</ci_lower_limit>
            <ci_upper_limit>-0.143</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 at 2 Hours on Day 1</title>
        <time_frame>2 hour</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 at 2 Hours on Day 1</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Least Squares Mean</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.293" spread="0.014"/>
                    <measurement group_id="O2" value="1.43" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.136</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.175</ci_lower_limit>
            <ci_upper_limit>-0.097</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 at 3 Hours on Day 1</title>
        <time_frame>3 hour</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 at 3 Hours on Day 1</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29" spread="0.015"/>
                    <measurement group_id="O2" value="1.375" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.084</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.125</ci_lower_limit>
            <ci_upper_limit>-0.044</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 at 4 Hours on Day 1</title>
        <time_frame>4 hour</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 at 4 Hours on Day 1</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.284" spread="0.015"/>
                    <measurement group_id="O2" value="1.319" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0997</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.035</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.076</ci_lower_limit>
            <ci_upper_limit>0.007</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 at 6 Hours on Day 1</title>
        <time_frame>6 hours</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 at 6 Hours on Day 1</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.269" spread="0.016"/>
                    <measurement group_id="O2" value="1.233" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.101</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.037</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.007</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 at -10 Minutes at Week 6</title>
        <time_frame>10 minutes before dosing</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 at -10 Minutes at Week 6</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.254" spread="0.017"/>
                    <measurement group_id="O2" value="1.108" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.145</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.098</ci_lower_limit>
            <ci_upper_limit>0.193</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 at 15 Minutes at Week 6</title>
        <time_frame>15 minutes</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 at 15 Minutes at Week 6</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.019"/>
                    <measurement group_id="O2" value="1.355" spread="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0411</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.055</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.108</ci_lower_limit>
            <ci_upper_limit>-0.002</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 at 30 Minutes at Week 6</title>
        <time_frame>30 minutes</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 at 30 Minutes at Week 6</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.328" spread="0.02"/>
                    <measurement group_id="O2" value="1.388" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0354</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.116</ci_lower_limit>
            <ci_upper_limit>-0.004</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 at 1 Hour at Week 6</title>
        <time_frame>1 hour</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 at 1 Hour at Week 6</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.343" spread="0.021"/>
                    <measurement group_id="O2" value="1.405" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.041</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.062</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.121</ci_lower_limit>
            <ci_upper_limit>-0.003</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 at 2 Hours at Week 6</title>
        <time_frame>2 hour</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 at 2 Hours at Week 6</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.364" spread="0.021"/>
                    <measurement group_id="O2" value="1.382" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5387</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.018</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.076</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 at 3 Hours at Week 6</title>
        <time_frame>3 hour</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 at 3 Hours at Week 6</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.371" spread="0.021"/>
                    <measurement group_id="O2" value="1.31" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0372</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.061</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.004</ci_lower_limit>
            <ci_upper_limit>0.118</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 at 4 Hours at Week 6</title>
        <time_frame>4 hour</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 at 4 Hours at Week 6</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.369" spread="0.02"/>
                    <measurement group_id="O2" value="1.247" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.121</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.066</ci_lower_limit>
            <ci_upper_limit>0.177</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 at 6 Hours at Week 6</title>
        <time_frame>6 hour</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 at 6 Hours at Week 6</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="0.019"/>
                    <measurement group_id="O2" value="1.168" spread="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.162</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.108</ci_lower_limit>
            <ci_upper_limit>0.216</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 at -10 Minutes at Week 12</title>
        <time_frame>10 minutes before dosing</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 at -10 Minutes at Week 12</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.225" spread="0.018"/>
                    <measurement group_id="O2" value="1.119" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.106</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.055</ci_lower_limit>
            <ci_upper_limit>0.157</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 at 15 Minutes at Week 12</title>
        <time_frame>15 minutes</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 at 15 Minutes at Week 12</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.268" spread="0.019"/>
                    <measurement group_id="O2" value="1.351" spread="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0023</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.083</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.136</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 at 30 Minutes at Week 12</title>
        <time_frame>30 minutes</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 at 30 Minutes at Week 12</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.306" spread="0.02"/>
                    <measurement group_id="O2" value="1.393" spread="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0019</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.087</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.142</ci_lower_limit>
            <ci_upper_limit>-0.033</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 at 1 Hour at Week 12</title>
        <time_frame>1 hour</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 at 1 Hour at Week 12</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.327" spread="0.02"/>
                    <measurement group_id="O2" value="1.41" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0044</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.083</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.139</ci_lower_limit>
            <ci_upper_limit>-0.026</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 at 2 Hours at Week 12</title>
        <time_frame>2 hour</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 at 2 Hours at Week 12</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.353" spread="0.021"/>
                    <measurement group_id="O2" value="1.398" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1182</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.046</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.103</ci_lower_limit>
            <ci_upper_limit>0.012</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 at 3 Hours at Week 12</title>
        <time_frame>3 hour</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 at 3 Hours at Week 12</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.353" spread="0.021"/>
                    <measurement group_id="O2" value="1.333" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4814</p_value>
            <p_value_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.037</ci_lower_limit>
            <ci_upper_limit>0.078</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 at 4 Hours at Week 12</title>
        <time_frame>4 hour</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 at 4 Hours at Week 12</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.337" spread="0.02"/>
                    <measurement group_id="O2" value="1.263" spread="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.074</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.019</ci_lower_limit>
            <ci_upper_limit>0.129</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 at 6 Hours at Week 12</title>
        <time_frame>6 hour</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 at 6 Hours at Week 12</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.318" spread="0.019"/>
                    <measurement group_id="O2" value="1.182" spread="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.136</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.082</ci_lower_limit>
            <ci_upper_limit>0.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC at 15 Minutes on Day 1</title>
        <time_frame>15 minutes</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FVC at 15 Minutes on Day 1</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.938" spread="0.036"/>
                    <measurement group_id="O2" value="3.308" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.449</ci_lower_limit>
            <ci_upper_limit>-0.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC at 30 Minutes on Day 1</title>
        <time_frame>30 minutes</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FVC at 30 Minutes on Day 1</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.044" spread="0.03"/>
                    <measurement group_id="O2" value="3.4" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.356</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.44</ci_lower_limit>
            <ci_upper_limit>-0.272</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC at 1 Hour on Day 1</title>
        <time_frame>1 hour</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FVC at 1 Hour on Day 1</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.087" spread="0.033"/>
                    <measurement group_id="O2" value="3.444" spread="0.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.357</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.451</ci_lower_limit>
            <ci_upper_limit>-0.264</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC at 2 Hours on Day 1</title>
        <time_frame>2 hour</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FVC at 2 Hours on Day 1</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.103" spread="0.033"/>
                    <measurement group_id="O2" value="3.388" spread="0.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.285</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.376</ci_lower_limit>
            <ci_upper_limit>-0.194</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC at 3 Hours on Day 1</title>
        <time_frame>3 hour</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FVC at 3 Hours on Day 1</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.091" spread="0.033"/>
                    <measurement group_id="O2" value="3.261" spread="0.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.261</ci_lower_limit>
            <ci_upper_limit>-0.079</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC at 4 Hours on Day 1</title>
        <time_frame>4 hour</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FVC at 4 Hours on Day 1</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.087" spread="0.034"/>
                    <measurement group_id="O2" value="3.136" spread="0.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2992</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.143</ci_lower_limit>
            <ci_upper_limit>0.044</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC at 6 Hours on Day 1</title>
        <time_frame>6 hour</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FVC at 6 Hours on Day 1</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.053" spread="0.034"/>
                    <measurement group_id="O2" value="2.972" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0984</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.081</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.015</ci_lower_limit>
            <ci_upper_limit>0.177</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC at -10 Minutes at Week 6</title>
        <time_frame>10 minutes before dosing</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FVC at -10 Minutes at Week 6</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="0.036"/>
                    <measurement group_id="O2" value="2.722" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.278</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.178</ci_lower_limit>
            <ci_upper_limit>0.379</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC at 15 Minutes at Week 6</title>
        <time_frame>15 minutes</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FVC at 15 Minutes at Week 6</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.09" spread="0.037"/>
                    <measurement group_id="O2" value="3.279" spread="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.189</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.293</ci_lower_limit>
            <ci_upper_limit>-0.086</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC at 30 Minutes at Week 6</title>
        <time_frame>30 minutes</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FVC at 30 Minutes at Week 6</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.158" spread="0.039"/>
                    <measurement group_id="O2" value="3.362" spread="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.204</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.314</ci_lower_limit>
            <ci_upper_limit>-0.095</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC at 1 Hour at Week 6</title>
        <time_frame>1 hour</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FVC at 1 Hour at Week 6</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.206" spread="0.04"/>
                    <measurement group_id="O2" value="3.388" spread="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1832</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.293</ci_lower_limit>
            <ci_upper_limit>-0.072</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC at 2 Hours at Week 6</title>
        <time_frame>2 hour</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FVC at 2 Hours at Week 6</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.227" spread="0.039"/>
                    <measurement group_id="O2" value="3.338" spread="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.044</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.097</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.219</ci_lower_limit>
            <ci_upper_limit>0.003</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC at 3 Hours at Week 6</title>
        <time_frame>3 hour</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FVC at 3 Hours at Week 6</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.235" spread="0.039"/>
                    <measurement group_id="O2" value="3.185" spread="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3634</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.058</ci_lower_limit>
            <ci_upper_limit>0.158</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC at 4 Hours at Week 6</title>
        <time_frame>4 hour</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FVC at 4 Hours at Week 6</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.23" spread="0.039"/>
                    <measurement group_id="O2" value="3.068" spread="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0032</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.163</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.055</ci_lower_limit>
            <ci_upper_limit>0.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC at 6 Hours at Week 6</title>
        <time_frame>6 hour</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FVC at 6 Hours at Week 6</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.190" spread="0.037"/>
                    <measurement group_id="O2" value="2.914" spread="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.275</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.173</ci_lower_limit>
            <ci_upper_limit>0.378</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC at -10 Minutes at Week 12</title>
        <time_frame>10 minutes before dosing</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FVC at -10 Minutes at Week 12</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.967" spread="0.039"/>
                    <measurement group_id="O2" value="2.792" spread="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0015</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.175</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.067</ci_lower_limit>
            <ci_upper_limit>0.283</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC at 15 Minutes at Week 12</title>
        <time_frame>15 minutes</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FVC at 15 Minutes at Week 12</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.069" spread="0.037"/>
                    <measurement group_id="O2" value="3.263" spread="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.193</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.296</ci_lower_limit>
            <ci_upper_limit>-0.091</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC at 30 Minutes at Week 12</title>
        <time_frame>30 minutes</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FVC at 30 Minutes at Week 12</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.143" spread="0.039"/>
                    <measurement group_id="O2" value="3.358" spread="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.215</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.323</ci_lower_limit>
            <ci_upper_limit>-0.108</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC at 1 Hour at Week 12</title>
        <time_frame>1 hour</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FVC at 1 Hour at Week 12</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.177" spread="0.04"/>
                    <measurement group_id="O2" value="3.375" spread="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.198</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.309</ci_lower_limit>
            <ci_upper_limit>-0.086</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC at 2 Hours at Week 12</title>
        <time_frame>2 hour</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FVC at 2 Hours at Week 12</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.231" spread="0.04"/>
                    <measurement group_id="O2" value="3.328" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0896</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.097</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.21</ci_lower_limit>
            <ci_upper_limit>0.015</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC at 3 Hours at Week 12</title>
        <time_frame>3 hour</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FVC at 3 Hours at Week 12</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.226" spread="0.04"/>
                    <measurement group_id="O2" value="3.218" spread="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8937</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.008</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.103</ci_lower_limit>
            <ci_upper_limit>0.118</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC at 4 Hours at Week 12</title>
        <time_frame>4 hour</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FVC at 4 Hours at Week 12</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.199" spread="0.04"/>
                    <measurement group_id="O2" value="3.074" spread="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0269</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.125</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.014</ci_lower_limit>
            <ci_upper_limit>0.236</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC at 6 Hours at Week 12</title>
        <time_frame>6 hour</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>FVC at 6 Hours at Week 12</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.155" spread="0.04"/>
                    <measurement group_id="O2" value="2.932" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.223</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.111</ci_lower_limit>
            <ci_upper_limit>0.335</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day Time Albuterol Use During Week 1</title>
        <description>Puffs of rescue albuterol used during the day in week 1</description>
        <time_frame>Week 1</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Day Time Albuterol Use During Week 1</title>
          <description>Puffs of rescue albuterol used during the day in week 1</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Puffs per day</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.175" spread="0.084"/>
                    <measurement group_id="O2" value="1.217" spread="0.082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7196</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.042</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.275</ci_lower_limit>
            <ci_upper_limit>0.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day Time Albuterol Use During Week 2</title>
        <description>Puffs of rescue albuterol used during the day in week 2</description>
        <time_frame>Week 2</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Day Time Albuterol Use During Week 2</title>
          <description>Puffs of rescue albuterol used during the day in week 2</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Puffs per day</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" spread="0.099"/>
                    <measurement group_id="O2" value="1.309" spread="0.096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6189</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.069</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.343</ci_lower_limit>
            <ci_upper_limit>0.205</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day Time Albuterol Use During Week 3</title>
        <description>Puffs of rescue albuterol used during the day in week 3</description>
        <time_frame>Week 3</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Day Time Albuterol Use During Week 3</title>
          <description>Puffs of rescue albuterol used during the day in week 3</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Puffs per day</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.337" spread="0.104"/>
                    <measurement group_id="O2" value="1.41" spread="0.101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6197</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.073</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.36</ci_lower_limit>
            <ci_upper_limit>0.215</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day Time Albuterol Use During Week 4</title>
        <description>Puffs of rescue albuterol used during the day in week 4</description>
        <time_frame>Week 4</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Day Time Albuterol Use During Week 4</title>
          <description>Puffs of rescue albuterol used during the day in week 4</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Puffs per day</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.287" spread="0.107"/>
                    <measurement group_id="O2" value="1.399" spread="0.104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4582</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.112</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.408</ci_lower_limit>
            <ci_upper_limit>0.184</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day Time Albuterol Use During Week 5</title>
        <description>Puffs of rescue albuterol used during the day in week 5</description>
        <time_frame>Week 5</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Day Time Albuterol Use During Week 5</title>
          <description>Puffs of rescue albuterol used during the day in week 5</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Puffs per day</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.275" spread="0.11"/>
                    <measurement group_id="O2" value="1.345" spread="0.107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6538</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.376</ci_lower_limit>
            <ci_upper_limit>0.236</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day Time Albuterol Use During Week 6</title>
        <description>Puffs of rescue albuterol used during the day in week 6</description>
        <time_frame>Week 6</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Day Time Albuterol Use During Week 6</title>
          <description>Puffs of rescue albuterol used during the day in week 6</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Puffs per day</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.259" spread="0.126"/>
                    <measurement group_id="O2" value="1.405" spread="0.123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4145</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.145</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.495</ci_lower_limit>
            <ci_upper_limit>0.205</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day Time Albuterol Use During Week 7</title>
        <description>Puffs of rescue albuterol used during the day in week 7</description>
        <time_frame>Week 7</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Day Time Albuterol Use During Week 7</title>
          <description>Puffs of rescue albuterol used during the day in week 7</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Puffs per day</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.313" spread="0.116"/>
                    <measurement group_id="O2" value="1.398" spread="0.114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6048</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.085</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.408</ci_lower_limit>
            <ci_upper_limit>0.238</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day Time Albuterol Use During Week 8</title>
        <description>Puffs of rescue albuterol used during the day in week 8</description>
        <time_frame>Week 8</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Day Time Albuterol Use During Week 8</title>
          <description>Puffs of rescue albuterol used during the day in week 8</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Puffs per day</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.301" spread="0.119"/>
                    <measurement group_id="O2" value="1.471" spread="0.117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3137</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.503</ci_lower_limit>
            <ci_upper_limit>0.162</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day Time Albuterol Use During Week 9</title>
        <description>Puffs of rescue albuterol used during the day in week 9</description>
        <time_frame>Week 9</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Day Time Albuterol Use During Week 9</title>
          <description>Puffs of rescue albuterol used during the day in week 9</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Puffs per day</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.369" spread="0.12"/>
                    <measurement group_id="O2" value="1.43" spread="0.117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7195</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.061</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.395</ci_lower_limit>
            <ci_upper_limit>0.273</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day Time Albuterol Use During Week 10</title>
        <description>Puffs of rescue albuterol used during the day in week 10</description>
        <time_frame>Week 10</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Day Time Albuterol Use During Week 10</title>
          <description>Puffs of rescue albuterol used during the day in week 10</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Puffs per day</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.351" spread="0.116"/>
                    <measurement group_id="O2" value="1.394" spread="0.114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7947</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.043</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.367</ci_lower_limit>
            <ci_upper_limit>0.282</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day Time Albuterol Use During Week 11</title>
        <description>Puffs of rescue albuterol used during the day in week 11</description>
        <time_frame>Week 11</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Day Time Albuterol Use During Week 11</title>
          <description>Puffs of rescue albuterol used during the day in week 11</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Puffs per day</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.352" spread="0.127"/>
                    <measurement group_id="O2" value="1.445" spread="0.124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6049</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.093</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.446</ci_lower_limit>
            <ci_upper_limit>0.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day Time Albuterol Use During Week 12</title>
        <description>Puffs of rescue albuterol used during the day in week 12</description>
        <time_frame>Week 12</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Day Time Albuterol Use During Week 12</title>
          <description>Puffs of rescue albuterol used during the day in week 12</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Puffs per day</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.361" spread="0.139"/>
                    <measurement group_id="O2" value="1.409" spread="0.137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8109</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.047</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.437</ci_lower_limit>
            <ci_upper_limit>0.342</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Night Time Albuterol Use During Week 1</title>
        <time_frame>Week 1</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Night Time Albuterol Use During Week 1</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Puffs per night</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.493" spread="0.259"/>
                    <measurement group_id="O2" value="2.966" spread="0.248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1471</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.527</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.186</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Night Time Albuterol Use During Week 2</title>
        <description>Puffs of rescue albuterol used during the night in week 2</description>
        <time_frame>Week 2</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Night Time Albuterol Use During Week 2</title>
          <description>Puffs of rescue albuterol used during the night in week 2</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Puffs per night</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.269" spread="0.19"/>
                    <measurement group_id="O2" value="3.004" spread="0.182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3192</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.265</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.258</ci_lower_limit>
            <ci_upper_limit>0.788</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Night Time Albuterol Use During Week 3</title>
        <description>Puffs of rescue albuterol used during the night in week 3</description>
        <time_frame>Week 3</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Night Time Albuterol Use During Week 3</title>
          <description>Puffs of rescue albuterol used during the night in week 3</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Puffs per night</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.282" spread="0.187"/>
                    <measurement group_id="O2" value="2.931" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.182</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.351</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.165</ci_lower_limit>
            <ci_upper_limit>0.867</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Night Time Albuterol Use During Week 4</title>
        <description>Puffs of rescue albuterol used during the night in week 4</description>
        <time_frame>Week 4</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Night Time Albuterol Use During Week 4</title>
          <description>Puffs of rescue albuterol used during the night in week 4</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Puffs per night</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.285" spread="0.193"/>
                    <measurement group_id="O2" value="2.921" spread="0.184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1777</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.363</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.166</ci_lower_limit>
            <ci_upper_limit>0.893</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Night Time Albuterol Use During Week 5</title>
        <description>Puffs of rescue albuterol used during the night in week 5</description>
        <time_frame>Week 5</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Night Time Albuterol Use During Week 5</title>
          <description>Puffs of rescue albuterol used during the night in week 5</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Puffs per night</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.152" spread="0.194"/>
                    <measurement group_id="O2" value="2.789" spread="0.185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1805</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.363</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.169</ci_lower_limit>
            <ci_upper_limit>0.895</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Night Time Albuterol Use During Week 6</title>
        <description>Puffs of rescue albuterol used during the night in week 6</description>
        <time_frame>Week 6</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Night Time Albuterol Use During Week 6</title>
          <description>Puffs of rescue albuterol used during the night in week 6</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Puffs per night</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.178" spread="0.197"/>
                    <measurement group_id="O2" value="2.806" spread="0.188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1777</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.372</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.17</ci_lower_limit>
            <ci_upper_limit>0.913</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Night Time Albuterol Use During Week 7</title>
        <description>Puffs of rescue albuterol used during the night in week 7</description>
        <time_frame>Week 7</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Night Time Albuterol Use During Week 7</title>
          <description>Puffs of rescue albuterol used during the night in week 7</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Puffs per night</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.156" spread="0.201"/>
                    <measurement group_id="O2" value="2.966" spread="0.193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5725</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.159</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.395</ci_lower_limit>
            <ci_upper_limit>0.714</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Night Time Albuterol Use During Week 8</title>
        <description>Puffs of rescue albuterol used during the night in week 8</description>
        <time_frame>Week 8</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Night Time Albuterol Use During Week 8</title>
          <description>Puffs of rescue albuterol used during the night in week 8</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Puffs per night</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.104" spread="0.207"/>
                    <measurement group_id="O2" value="2.983" spread="0.198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6765</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.121</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.449</ci_lower_limit>
            <ci_upper_limit>0.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Night Time Albuterol Use During Week 9</title>
        <description>Puffs of rescue albuterol used during the night in week 9</description>
        <time_frame>Week 9</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Night Time Albuterol Use During Week 9</title>
          <description>Puffs of rescue albuterol used during the night in week 9</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Puffs per night</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.254" spread="0.208"/>
                    <measurement group_id="O2" value="3.006" spread="0.198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3943</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.247</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.323</ci_lower_limit>
            <ci_upper_limit>0.818</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Night Time Albuterol Use During Week 10</title>
        <description>Puffs of rescue albuterol used during the night in week 10</description>
        <time_frame>Week 10</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Night Time Albuterol Use During Week 10</title>
          <description>Puffs of rescue albuterol used during the night in week 10</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Puffs per night</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.199" spread="0.203"/>
                    <measurement group_id="O2" value="2.909" spread="0.196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3091</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.291</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.271</ci_lower_limit>
            <ci_upper_limit>0.852</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Night Time Albuterol Use During Week 11</title>
        <description>Puffs of rescue albuterol used during the night in week 11</description>
        <time_frame>Week 11</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Night Time Albuterol Use During Week 11</title>
          <description>Puffs of rescue albuterol used during the night in week 11</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Puffs per night</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.224" spread="0.214"/>
                    <measurement group_id="O2" value="2.907" spread="0.205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2911</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.317</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.273</ci_lower_limit>
            <ci_upper_limit>0.907</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Night Time Albuterol Use During Week 12</title>
        <description>Puffs of rescue albuterol used during the night in week 12</description>
        <time_frame>Week 12</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Night Time Albuterol Use During Week 12</title>
          <description>Puffs of rescue albuterol used during the night in week 12</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Puffs per night</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.178" spread="0.238"/>
                    <measurement group_id="O2" value="3.069" spread="0.229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7458</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.108</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.549</ci_lower_limit>
            <ci_upper_limit>0.766</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning Peak Expiratory Flow Rate (PEFR) at Week 1</title>
        <time_frame>Week 1</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Morning Peak Expiratory Flow Rate (PEFR) at Week 1</title>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters/minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205.8" spread="2.1"/>
                    <measurement group_id="O2" value="195.1" spread="2.059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>10.698</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.836</ci_lower_limit>
            <ci_upper_limit>16.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning PEFR at Week 2</title>
        <description>Weekly means for morning PEFR</description>
        <time_frame>Week 2</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Morning PEFR at Week 2</title>
          <description>Weekly means for morning PEFR</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters/minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.07" spread="2.594"/>
                    <measurement group_id="O2" value="194.81" spread="2.516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0023</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>11.257</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.055</ci_lower_limit>
            <ci_upper_limit>18.458</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning PEFR at Week 3</title>
        <description>Weekly means for morning PEFR</description>
        <time_frame>Week 3</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Morning PEFR at Week 3</title>
          <description>Weekly means for morning PEFR</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters/minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.61" spread="2.816"/>
                    <measurement group_id="O2" value="193.83" spread="2.742"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0015</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>12.772</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.942</ci_lower_limit>
            <ci_upper_limit>20.602</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning PEFR at Week 4</title>
        <description>Weekly means for morning PEFR</description>
        <time_frame>Week 4</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Morning PEFR at Week 4</title>
          <description>Weekly means for morning PEFR</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters/minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.76" spread="2.959"/>
                    <measurement group_id="O2" value="193.19" spread="2.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0013</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>13.568</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>5.342</ci_lower_limit>
            <ci_upper_limit>21.795</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning PEFR at Week 5</title>
        <description>Weekly means for morning PEFR</description>
        <time_frame>Week 5</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Morning PEFR at Week 5</title>
          <description>Weekly means for morning PEFR</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters/minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205.6" spread="3.012"/>
                    <measurement group_id="O2" value="193.55" spread="2.932"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>12.052</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.676</ci_lower_limit>
            <ci_upper_limit>20.428</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning PEFR at Week 6</title>
        <description>Weekly means for morning PEFR</description>
        <time_frame>Week 6</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Morning PEFR at Week 6</title>
          <description>Weekly means for morning PEFR</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters/minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.49" spread="3.236"/>
                    <measurement group_id="O2" value="195.38" spread="3.158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0159</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>11.107</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.095</ci_lower_limit>
            <ci_upper_limit>20.119</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning PEFR at Week 7</title>
        <description>Weekly means for morning PEFR</description>
        <time_frame>Week 7</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Morning PEFR at Week 7</title>
          <description>Weekly means for morning PEFR</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters/minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208.72" spread="3.377"/>
                    <measurement group_id="O2" value="197.66" spread="3.326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0219</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>11.057</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.613</ci_lower_limit>
            <ci_upper_limit>20.501</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning PEFR at Week 8</title>
        <description>Weekly means for morning PEFR</description>
        <time_frame>Week 8</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Morning PEFR at Week 8</title>
          <description>Weekly means for morning PEFR</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters/minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208.88" spread="3.385"/>
                    <measurement group_id="O2" value="195.22" spread="3.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0048</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>13.655</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.207</ci_lower_limit>
            <ci_upper_limit>23.104</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning PEFR at Week 9</title>
        <description>Weekly means for morning PEFR</description>
        <time_frame>Week 9</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Morning PEFR at Week 9</title>
          <description>Weekly means for morning PEFR</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters/minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208.97" spread="3.621"/>
                    <measurement group_id="O2" value="194.74" spread="3.531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0058</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>14.231</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.153</ci_lower_limit>
            <ci_upper_limit>24.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning PEFR at Week 10</title>
        <description>Weekly means for morning PEFR</description>
        <time_frame>Week 10</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Morning PEFR at Week 10</title>
          <description>Weekly means for morning PEFR</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters/minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204.83" spread="3.608"/>
                    <measurement group_id="O2" value="193.23" spread="3.568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0248</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>11.597</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.483</ci_lower_limit>
            <ci_upper_limit>21.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning PEFR at Week 11</title>
        <description>Weekly means for morning PEFR</description>
        <time_frame>Week 11</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Morning PEFR at Week 11</title>
          <description>Weekly means for morning PEFR</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters/minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.47" spread="3.607"/>
                    <measurement group_id="O2" value="195.47" spread="3.542"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0325</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>11.001</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.924</ci_lower_limit>
            <ci_upper_limit>21.079</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning PEFR at Week 12</title>
        <description>Weekly means for morning PEFR</description>
        <time_frame>Week 12</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Morning PEFR at Week 12</title>
          <description>Weekly means for morning PEFR</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters/minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.52" spread="4.408"/>
                    <measurement group_id="O2" value="192.44" spread="3.996"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0153</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>14.074</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.726</ci_lower_limit>
            <ci_upper_limit>25.422</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evening PEFR at Week 1</title>
        <description>Weekly means for evening PEFR</description>
        <time_frame>Week 1</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Evening PEFR at Week 1</title>
          <description>Weekly means for evening PEFR</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters/minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222.89" spread="2.459"/>
                    <measurement group_id="O2" value="222.64" spread="2.352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6105</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.755</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-8.532</ci_lower_limit>
            <ci_upper_limit>5.022</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evening PEFR at Week 2</title>
        <description>Weekly means for evening PEFR</description>
        <time_frame>Week 2</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Evening PEFR at Week 2</title>
          <description>Weekly means for evening PEFR</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters/minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="221.97" spread="2.715"/>
                    <measurement group_id="O2" value="221.12" spread="2.596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8249</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.842</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.642</ci_lower_limit>
            <ci_upper_limit>8.326</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evening PEFR at Week 3</title>
        <description>Weekly means for evening PEFR</description>
        <time_frame>Week 3</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Evening PEFR at Week 3</title>
          <description>Weekly means for evening PEFR</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters/minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="221.23" spread="2.793"/>
                    <measurement group_id="O2" value="218.52" spread="2.681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4896</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.001</ci_lower_limit>
            <ci_upper_limit>10.421</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evening PEFR at Week 4</title>
        <description>Weekly means for evening PEFR</description>
        <time_frame>Week 4</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Evening PEFR at Week 4</title>
          <description>Weekly means for evening PEFR</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters/minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="221.96" spread="2.933"/>
                    <measurement group_id="O2" value="215.06" spread="2.796"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0935</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.898</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.172</ci_lower_limit>
            <ci_upper_limit>14.968</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evening PEFR at Week 5</title>
        <description>Weekly means for evening PEFR</description>
        <time_frame>Week 5</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Evening PEFR at Week 5</title>
          <description>Weekly means for evening PEFR</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters/minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217.95" spread="3.125"/>
                    <measurement group_id="O2" value="214.53" spread="2.977"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4339</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.419</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.17</ci_lower_limit>
            <ci_upper_limit>12.007</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evening PEFR at Week 6</title>
        <description>Weekly means for evening PEFR</description>
        <time_frame>Week 6</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Evening PEFR at Week 6</title>
          <description>Weekly means for evening PEFR</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters/minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218.45" spread="3.535"/>
                    <measurement group_id="O2" value="219.42" spread="3.382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.845</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.971</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-10.74</ci_lower_limit>
            <ci_upper_limit>8.799</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evening PEFR at Week 7</title>
        <description>Weekly means for evening PEFR</description>
        <time_frame>Week 7</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Evening PEFR at Week 7</title>
          <description>Weekly means for evening PEFR</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters/minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220.98" spread="3.63"/>
                    <measurement group_id="O2" value="220.79" spread="3.468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9696</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.194</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.811</ci_lower_limit>
            <ci_upper_limit>10.199</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evening PEFR at Week 8</title>
        <description>Weekly means for evening PEFR</description>
        <time_frame>Week 8</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Evening PEFR at Week 8</title>
          <description>Weekly means for evening PEFR</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters/minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223.33" spread="3.721"/>
                    <measurement group_id="O2" value="218.2" spread="3.553"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3252</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.129</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.117</ci_lower_limit>
            <ci_upper_limit>15.376</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evening PEFR at Week 9</title>
        <description>Weekly means for evening PEFR</description>
        <time_frame>Week 9</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Evening PEFR at Week 9</title>
          <description>Weekly means for evening PEFR</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters/minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="221.47" spread="3.86"/>
                    <measurement group_id="O2" value="217.41" spread="3.674"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.452</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.062</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.558</ci_lower_limit>
            <ci_upper_limit>14.683</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evening PEFR at Week 10</title>
        <description>Weekly means for evening PEFR</description>
        <time_frame>Week 10</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Evening PEFR at Week 10</title>
          <description>Weekly means for evening PEFR</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters/minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220.46" spread="3.808"/>
                    <measurement group_id="O2" value="216.32" spread="3.649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4388</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.372</ci_lower_limit>
            <ci_upper_limit>14.651</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evening PEFR at Week 11</title>
        <description>Weekly means for evening PEFR</description>
        <time_frame>Week 11</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Evening PEFR at Week 11</title>
          <description>Weekly means for evening PEFR</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters/minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218.35" spread="3.91"/>
                    <measurement group_id="O2" value="217.17" spread="3.724"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8288</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.185</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.595</ci_lower_limit>
            <ci_upper_limit>11.964</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evening PEFR at Week 12</title>
        <description>Weekly means for evening PEFR</description>
        <time_frame>Week 12</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Evening PEFR at Week 12</title>
          <description>Weekly means for evening PEFR</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Liters/minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219.66" spread="4.371"/>
                    <measurement group_id="O2" value="215.46" spread="4.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4929</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.204</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-7.857</ci_lower_limit>
            <ci_upper_limit>16.264</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Evaluation</title>
        <description>The Patient Global Evaluation reflected the patient's opinion of their overall condition with respect to chronic obstructive pulmonary disease (COPD). The scale responses were: Poor (1,2). Fair (3,4), Good (5,6) and Excellent (7,8)</description>
        <time_frame>Week 6</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Evaluation</title>
          <description>The Patient Global Evaluation reflected the patient's opinion of their overall condition with respect to chronic obstructive pulmonary disease (COPD). The scale responses were: Poor (1,2). Fair (3,4), Good (5,6) and Excellent (7,8)</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.273" spread="0.081"/>
                    <measurement group_id="O2" value="4.069" spread="0.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0754</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.204</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.021</ci_lower_limit>
            <ci_upper_limit>0.429</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Evaluation</title>
        <description>The Patient Global Evaluation reflected the patient's opinion of their overall condition with respect to COPD. The scale responses were: Poor (1,2). Fair (3,4), Good (5,6) and Excellent (7,8).</description>
        <time_frame>Week 12</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Evaluation</title>
          <description>The Patient Global Evaluation reflected the patient's opinion of their overall condition with respect to COPD. The scale responses were: Poor (1,2). Fair (3,4), Good (5,6) and Excellent (7,8).</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.49" spread="0.1"/>
                    <measurement group_id="O2" value="4.239" spread="0.098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0765</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.251</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.027</ci_lower_limit>
            <ci_upper_limit>0.528</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician Global Evaluation</title>
        <description>The Physician Global Evaluation reflected the physician's opinion of the patients overall condition with respect to COPD. The scale responses were: Poor (1,2). Fair (3,4), Good (5,6) and Excellent (7,8).</description>
        <time_frame>Week 6</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Physician Global Evaluation</title>
          <description>The Physician Global Evaluation reflected the physician's opinion of the patients overall condition with respect to COPD. The scale responses were: Poor (1,2). Fair (3,4), Good (5,6) and Excellent (7,8).</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.867" spread="0.076"/>
                    <measurement group_id="O2" value="4.716" spread="0.075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.163</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.151</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.061</ci_lower_limit>
            <ci_upper_limit>0.363</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician Global Evaluation</title>
        <description>The Physician Global Evaluation reflected the physician's opinion of the patients overall condition with respect to COPD. The scale responses were: Poor (1,2). Fair (3,4), Good (5,6) and Excellent (7,8).</description>
        <time_frame>Week 12</time_frame>
        <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>18 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Combivent (Ipratropium/Albuterol)</title>
            <description>2 actuations 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Physician Global Evaluation</title>
          <description>The Physician Global Evaluation reflected the physician's opinion of the patients overall condition with respect to COPD. The scale responses were: Poor (1,2). Fair (3,4), Good (5,6) and Excellent (7,8).</description>
          <population>Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.057" spread="0.076"/>
                    <measurement group_id="O2" value="4.772" spread="0.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0085</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.285</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.073</ci_lower_limit>
            <ci_upper_limit>0.496</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first drug administration until 30 days after last drug adminsitration</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tiotropium</title>
          <description>18 mcg once daily</description>
        </group>
        <group group_id="E2">
          <title>Combivent (Ipratropium/Albuterol)</title>
          <description>2 actuations 4 times daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroesophageal Reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Small intestional obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

